Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tyrosine phosphorylation in human lymphomas.

E Haralambieva1, M Jones, G M Roncador

  • 1Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK.

The Histochemical Journal
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Leukemia·2026
Same author

Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.

Leukemia·2025
Same author

Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target.

Nature communications·2025
Same author

FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.

EJHaem·2023
Same author

Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.

Leukemia & lymphoma·2023
Same author

Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway.

The British journal of dermatology·2021
Same journal

Glycosylation of the male genital ducts and spermatozeugmata formation in the clearnose skate Raja eglanteria.

The Histochemical journal·2003
Same journal

Expression pattern of glycoconjugates in rat retina as analysed by lectin histochemistry.

The Histochemical journal·2003
Same journal

Autometallographic localization of heavy metals in resin sections, cryosections and isolated cells of the mussel Mytilus galloprovincialis (L.).

The Histochemical journal·2003
Same journal

Changes in the thymus of peripubertal rats induced by centrally applied somatostatin-28.

The Histochemical journal·2003
Same journal

Localization of endogenous biotin-containing proteins in mouse Bergmann glial cells.

The Histochemical journal·2003
Same journal

Immunolocalization of laminin-alpha1-like antigens around synapses in mouse cerebellar perineuronal nets.

The Histochemical journal·2003
See all related articles

Anaplastic lymphoma kinase-positive lymphomas show high protein tyrosine phosphorylation. This activation is likely not a major oncogenic event in other lymphoma subtypes, suggesting targeted therapies may be specific to ALK-positive cases.

Area of Science:

  • Oncology
  • Hematopathology
  • Molecular Biology

Background:

  • Protein tyrosine phosphorylation is elevated in anaplastic lymphoma kinase (ALK)-positive lymphomas.
  • Immunolabelling techniques can detect this phosphorylation in paraffin-embedded tissues.

Purpose of the Study:

  • To investigate oncogenic tyrosine kinase activation in various lymphoma subtypes.
  • To compare phosphotyrosine levels in ALK-positive anaplastic large cell lymphoma (ALCL) with other lymphomas.

Main Methods:

  • Immunohistochemical staining for phosphotyrosine was performed on 145 lymphoma cases.
  • Cases included ALK-positive ALCL, ALK-negative ALCL, and other B-cell and T-cell lymphomas.
  • Lymphomatoid papulosis cases were also analyzed.

Related Experiment Videos

Main Results:

  • 27/28 ALK-positive ALCL cases showed significant cytoplasmic phosphotyrosine labelling.
  • ALK-positive ALCL cases did not exhibit nuclear phosphotyrosine.
  • Variable, generally weaker phosphotyrosine labelling was found in some ALK-negative lymphomas, but not comparable to ALK-positive ALCL.

Conclusions:

  • Tyrosine kinase activation appears to be a key oncogenic event specifically in ALK-positive ALCL.
  • This activation is likely not a primary driver in most other lymphoma subtypes studied.
  • Findings suggest targeted therapies for ALK-positive lymphomas may not be effective in other lymphoma categories.